Nephrology

Agency requests additional analyses on the novel mechanism of action on the serum phosphorus treatment for chronic kidney disease patients on dialysis.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

Medtronic claims the GI Genius module will help clinicals identify lesions in real time during a colonoscopy.

Many believed radiocontrast exposure could be linked to long-term kidney impairment.

As a multi-systemic disorder, Fabry disease can impact the functions of various organs. As a genetic disorder, Fabry can impact the offsprings, parents, and relatives of the patient. Therefore, its effects are far-reaching.

Eric Wallace, MD, discusses Anderson-Fabry disease and the difficulties associated with screening, testing, and treatment.

COVID-19-associated AKI patients had fewer comorbidities compared to AKI patients without the viral infection.

The FDA will consider the approval of the biologics license application next month.

Traditional screenings for kidney allograft rejections can be expensive and invasive, highlighting the need for new methods.

Use of the vasoconstrictor was associated with increased risk for death due to respiratory disorders.

Risk was greater in children requiring intensive care, those with chronic kidney disease, and older patients.

Although overall decrease in mortality was similar to the control group, sickle cell populations were still less likely to receive a kidney transplant.

Individuals with PH are often undiagnosed or misdiagnosed; therefore, the exact prevalence of the disorder is unclear.

Prevalence of anemia in patients with chronic kidney disease on hemodialysis found higher in Mexico than studied populations, with similar contributing factors.

Investigators conclude improvements in kidney transplantation may require significant interventions.

The new study underscores the importance of annual urine analysis to catch signs of diabetic nephropathy.

New WORLDSymposium findings show a treated patient had 100% reduction in the accumulating fatty substrate associated with the burdensome rare disease after 1 year.

The adverse effects of corticosteroids have underscored a need to eliminate the drug from treatment regimens.

The University of Chicago hypertension expert discusses new ADA recommendations for cardiovascular risk management.

The treatment represents the first ever oral therapy approved by the FDA for lupus nephritis.

Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.

If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.

The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.

The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.